Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: J Invest Dermatol. 2015 Jun 3;135(10):2542–2544. doi: 10.1038/jid.2015.205

Figure 1. Incidence of secondary skin lesions by dose cohort of XL888.

Figure 1

Chart shows the incidence of hyperproliferative/neoplastic skin lesions (melanoma, SCC: squamous cell carcinoma, KA: keratoacanthoma, and VV: verucca vulgaris, stratified by XL888 dose cohort (cohort 1: 30mg; cohort 2: 45mg; cohort 3: 90mg; cohort 4: 135mg). Data shows number of lesions of each type for each individual patient. Cohort had 7 total events (3/3 patients), cohort 2 had 6 total events (2/3 patients), cohort 3 had 3 total events (2/3 patients) and cohort 4 had 3 total events (2/6 patients).